{"classes":[{"categories":[{"measurements":[{"comment":"Not estimable (NA) due to the insufficient number of participants with events","groupId":"OG000","lowerLimit":"12.0","upperLimit":"NA","value":"20.3"},{"comment":"Not estimable (NA) due to the insufficient number of participants with events","groupId":"OG001","lowerLimit":"6.6","upperLimit":"NA","value":"NA"}]}],"title":"Up to approx. 3 years"},{"categories":[{"measurements":[{"comment":"Not estimable (NA) due to the insufficient number of participants with events","groupId":"OG000","lowerLimit":"16.6","upperLimit":"NA","value":"30.0"},{"comment":"Not estimable (NA) due to the insufficient number of participants with events","groupId":"OG001","lowerLimit":"6.6","upperLimit":"NA","value":"19.4"}]}],"title":"Up to approx 4.2 years"}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"Time from first documented response (PR or CR) until disease progression or death as per RANO criteria. Confidence Intervals were estimated using the Brookmeyer Crowley method. Patients who had not progressed or died or had received further anticancer therapy, were censored at the date of the last adequate tumor evaluation.\n\nCR: Complete disappearance of all enhancing measurable and nonmeasurable disease sustained for at least 4 weeks; no new lesions; and stable or improved nonenhancing (T2/FLAIR) lesions. Patient must be off steroids or only on physiologic replacement doses.\n\nPR: ≥ 50% reduction, compared to baseline, in the sum of products of the perpendicular diameters for all measurable lesions for at least 4 weeks, no progression of nonmeasureable disease, no new lesions, and stable or improved nonenhancing (T2/FLAIR) lesions. Patient must be on a corticosteroid dose not greater than the dose at the time of baseline scan and be stable or improving clinically.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants in the LGG cohort randomized to receive dabrafenib (orally, twice daily and dosed based on weight and age) in combination with trametinib (orally, once daily in combination with the first daily dose of dabrafenib and was dosed based on weight)","id":"OG000","title":"LGG Cohort: Dabrafenib and Trametinib"},{"description":"Participants in the LGG cohort randomized to receive active comparator chemotherapy (carboplatin and vincristine). Participants received one course of induction (10 weeks of chemotherapy with 2 weeks of rest), followed by 8 cycles of maintenance chemotherapy. Participants were allowed to crossover to dabrafenib and trametinib after centrally confirmed and RANO-defined disease progression.","id":"OG001","title":"LGG Cohort: Carboplatin and Vincristine"}],"paramType":"MEDIAN","populationDescription":"Participants on the LGG cohort to whom study treatment had been assigned by randomization regardless of whether or not treatment was administered with a confirmed CR or PR as per central independent review assessment using RANO criteria. According to the intent to treat principle, patients were analyzed according to the treatment they had been assigned to during the randomization procedure.","reportingStatus":"POSTED","timeFrame":"Up to approx. 3 years and up to approx 4.2 years","title":"LGG Cohort: Kaplan-Meier Estimates of Duration of Response (DOR) as Per Central Independent Assessment Using RANO Criteria","type":"SECONDARY","unitOfMeasure":"Months"}